Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
The study of the pharmacokinetics and pharmacodynamics of platinum based anti-cancer drugs has done much to direct their development, at both preclinical and clinical levels. The clinical development of cisplatin depended on an understanding of its mechanism of action. The amelioration of the renal toxicity of cisplatin with sodium chloride infusion and forced diuresis is thought to rely on a common ion effect to suppress the formation of aquated species in the renal tubule. Studies of the modulation of cisplatin toxicity with other agents have followed, although none has yet achieved widespread acceptance. Following the demonstration of the important clinical role for cisplatin, studies of the relationship between toxicity and the reactivity of the leaving groups led to the development of the less toxic but equally effective analogue, carboplatin. The clinical development of carboplatin has in turn been strongly influenced by the studies of its pharmacokinetics, with pharmacokinetically guided dosing now being standard in many cancer centres and also being widely used in current clinical trials. Pharmacokinetic studies in animals have demonstrated that it is possible to make analogues that have good oral bioavailability. Apart from the convenience of oral administration, there is also the suggestion that these molecules may possess activity against certain cisplatin resistant cell lines. For the future, the development of sensitive methodologies whereby the exact types of platinum-DNA adducts formed can be characterized may allow the reason for the remarkable anti-tumour activity of these complexes to be elucidated and further, more selective compounds to be designed. The history of the development of platinum compounds emphasizes the importance of performing intensive pharmacokinetic, pharmacodynamic and mechanistic studies in concert with the clinical development of any class of agents.
Calvert
H
H
Cancer Research Unit, University of Newcastle upon Tyne, Medical School.
Judson
I
I
van der Vijgh
W J
WJ
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D004247:DNA / Q000378:metabolism; D004351:Drug Resistance; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D004247:DNA; D016190:Carboplatin